Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States

Tatar, Moosa; Keeshin, Susana; Mailliard, Mark E.; Wilson, Fernando A.

doi:10.1001/jamanetworkopen.2020.15756

Cited by 26 publications

(26 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Japanese study reached a similar conclusion that the GLE/PIB regimen is the best strategy among the four DAA regimens (7). In the US, the GLE/ PIB regimen is considered a better value-for-money DAA than its predecessors (39). Similar to the above studies, our findings suggest that the GLE/PIB regimen is cost-effective in Chinese patients.…”

Section: Discussionsupporting

confidence: 85%

Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection

Zhou

Wu²,

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) infection is an important health threat in China to which direct acting antivirals (DAAs) are very effective. In 2019, another novel DAA glecaprevir/pibrentasvir (GLE/ PIB) was officially approved. Knowledge of its cost-effectiveness would be informative for clinical decisionmaking but has not been evaluated. This study aims to evaluate the cost-effectiveness of GLE/PIB to inform policy-making on drug reimbursement and HCV eradication.Methods: Markov models were developed from the payers' perspective and simulated the lifetime experience of adult patients chronically infected with HCV genotype 1 or genotype 2. Two regimens, GLE/ PIB and pegylated interferon (pegIFN) plus ribavirin (RBV), were compared in cost and quality adjusted life years (QALY) with both outcomes being discounted to 2020 values. The incremental cost-effectiveness ratio (ICER) was computed to reflect the incremental benefit of GLE/PIB versus pegIFN + RBV. The robustness of the model outcomes was examined using deterministic and probabilistic sensitivity analysis (PSA) to identify influential parameters and to assess the probability of GLE/PIB being cost-effective. The GDP per capita in China in 2019 ($10,275) was used as the threshold for cost-effectiveness.

show abstract

Section: Discussionsupporting

confidence: 85%

Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection

Zhou

Wu²,

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…They estimated cost effectiveness comparing screening programs targeting PWIDs with the universal screening of United States adults. They concluded that HCV screening for PWIDs could potentially decrease the risk of untreated HCV infection and liver-related mortality and may thus be cost effective[ 410 ].…”

Section: Who Really Needs Treatment: the Proposed Policymentioning

confidence: 99%

Hepatitis C virus: A critical approach to who really needs treatment

Voumvouraki¹

2022

WJH

View full text Add to dashboard Cite

Introduction of effective drugs in the treatment of hepatitis C virus (HCV) infection has prompted the World Health Organization to declare a global eradication target by 2030. Propositions have been made to screen the general population and treat all HCV carriers irrespective of the disease status. A year ago the new severe acute respiratory syndrome coronavirus 2 virus appeared causing a worldwide pandemic of coronavirus disease 2019 disease. Huge financial resources were redirected, and the pandemic became the first priority in every country. In this review, we examined the feasibility of the World Health Organization elimination program and the actual natural course of HCV infection. We also identified and analyzed certain comorbidity factors that may aggravate the progress of HCV and some marginalized subpopulations with characteristics favoring HCV dissemination. Alcohol consumption, HIV coinfection and the presence of components of metabolic syndrome including obesity, hyperuricemia and overt diabetes were comorbidities mostly responsible for increased liver-related morbidity and mortality of HCV. We also examined the significance of special subpopulations like people who inject drugs and males having sex with males. Finally, we proposed a different micro-elimination screening and treatment program that can be implemented in all countries irrespective of income. We suggest that screening and treatment of HCV carriers should be limited only in these particular groups.

show abstract

“…intravenous drug users) and highly effective DAA treatments have also proven cost-effective in avoiding liver-related mortality and liver transplantations. 112 There are three targets of DAA therapy, including NS3/4A protease inhibitors, NS5A polymerase inhibitors, NS5B polymerase inhibitors. DAA therapy is highly effective, with SVR rates >95% in genotype 1-infected patients without cirrhosis including those co-infected with human immunodeficiency virus, and about 78–87% effective in decompensated cirrhotics with Child–Turcotte–Pugh class C disease.…”

Section: Hepatitis Cmentioning

confidence: 99%

A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis

Saraceni¹,

Birk²

2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

show abstract

Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States

Cited by 26 publications

References 58 publications

Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection

Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection

Hepatitis C virus: A critical approach to who really needs treatment

A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis

Contact Info

Product

Resources

About